IRIS
FRANCHINA, Tindara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.754
NA - Nord America 4.211
AS - Asia 2.464
SA - Sud America 830
AF - Africa 79
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 4
Totale 13.350
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.112
RU - Federazione Russa 2.950
SG - Singapore 1.027
BR - Brasile 706
CN - Cina 690
SE - Svezia 605
IE - Irlanda 585
IT - Italia 328
PL - Polonia 302
FR - Francia 295
HK - Hong Kong 275
DE - Germania 179
VN - Vietnam 142
UA - Ucraina 121
GB - Regno Unito 112
FI - Finlandia 102
IN - India 84
AT - Austria 46
AR - Argentina 42
CA - Canada 42
BD - Bangladesh 33
BE - Belgio 33
MX - Messico 31
IQ - Iraq 28
ZA - Sudafrica 28
ID - Indonesia 27
UZ - Uzbekistan 24
EC - Ecuador 23
TR - Turchia 22
NL - Olanda 19
CO - Colombia 18
JP - Giappone 15
PK - Pakistan 14
VE - Venezuela 14
ES - Italia 13
PH - Filippine 13
NP - Nepal 11
CZ - Repubblica Ceca 10
JM - Giamaica 10
MA - Marocco 10
CL - Cile 9
AL - Albania 8
EE - Estonia 8
SA - Arabia Saudita 8
LT - Lituania 7
TN - Tunisia 7
CI - Costa d'Avorio 6
DZ - Algeria 6
EG - Egitto 6
EU - Europa 6
KE - Kenya 6
JO - Giordania 5
PY - Paraguay 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LK - Sri Lanka 4
RO - Romania 4
CH - Svizzera 3
HR - Croazia 3
IR - Iran 3
MY - Malesia 3
PA - Panama 3
PE - Perù 3
RS - Serbia 3
SY - Repubblica araba siriana 3
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
CR - Costa Rica 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
IL - Israele 2
LB - Libano 2
LV - Lettonia 2
MD - Moldavia 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
DK - Danimarca 1
ET - Etiopia 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
Totale 13.338
Salva come PNG Salva come JPEG
Città #
Moscow 840
Ashburn 653
Dublin 583
Singapore 541
Chandler 489
Dallas 409
Nyköping 294
Warsaw 291
Hong Kong 275
Jacksonville 243
Beijing 238
San Jose 150
The Dalles 137
New York 133
Messina 124
Los Angeles 112
Ann Arbor 97
Dearborn 93
Princeton 93
Lauterbourg 83
Medford 82
Cambridge 74
Des Moines 70
São Paulo 55
Buffalo 46
Ho Chi Minh City 45
Munich 44
Boardman 41
Vienna 39
Tianjin 37
Woodbridge 35
Brussels 33
Frankfurt am Main 28
Pune 28
Council Bluffs 26
Dong Ket 24
Orem 23
San Mateo 23
Wilmington 23
Jinan 22
Shenyang 21
Tashkent 21
Hanoi 20
Redondo Beach 20
Belo Horizonte 18
Guangzhou 18
Jakarta 18
Turku 18
Chennai 17
Lancaster 17
Santa Clara 17
Stockholm 17
Johannesburg 16
Nanjing 16
Rio de Janeiro 16
Helsinki 15
London 15
Brasília 14
Brooklyn 14
Chicago 14
Fort Washington 14
Grammichele 14
Houston 14
Montreal 14
Atlanta 13
San Francisco 13
Tokyo 13
Amsterdam 12
Boston 12
Curitiba 12
Denver 12
Hebei 12
Shanghai 12
Manchester 11
Quito 11
Nuremberg 10
Porto Alegre 10
Taizhou 10
Campinas 9
Mexico City 9
Paternò 9
Seattle 9
Shenzhen 9
Toronto 9
Zhengzhou 9
Baghdad 8
Duque de Caxias 8
Düsseldorf 8
Hangzhou 8
Leawood 8
Mumbai 8
Phoenix 8
Caracas 7
Dhaka 7
Goiânia 7
Hyderabad 7
Istanbul 7
Jiaxing 7
Medellín 7
Milan 7
Totale 7.412
Salva come PNG Salva come JPEG
Nome #
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 238
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 228
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 216
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 215
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 208
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 202
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 196
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 194
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 191
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 187
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 182
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 179
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 176
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 173
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 172
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 171
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 171
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 170
Vaginal Mucosal Melanoma: a Complete Remission after Immunotherapy and '0-7-21' Radiotherapy Regimen (24 Gy/3 fractions/21 days) 169
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 168
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 164
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 164
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 164
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 163
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 162
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 161
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 160
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 156
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 155
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 154
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 152
Challenges and promises of physical exercise in advances lung cancer patients 151
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 149
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database 147
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 146
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 146
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 146
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 145
Embolia polmonare 142
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: a case report. 142
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 142
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 142
IL-33/IL-31 axis: A new pathological mechanism for epidermal growth factor receptor tyrosine kinase inhibitors-associated skin toxicity? 142
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 141
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 137
Impact of single-nucleotide polymorphisms in genes coding for folate pathway enzymes on efficacy/toxicity of gemcitabine and pemetrexed based therapy in advanced non small cell lung cancer (NSCLC): new prospectives for old markers. 136
Emerging targeted therapies for castration-resistant prostate cancer 136
Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer 135
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 134
NSCLC and HER2: between lights and shadows 131
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 128
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 127
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 125
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 125
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. 122
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 121
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 120
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 120
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 119
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 119
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 118
Molecular and clinical analysis of predictive biomarkers to anti-EGFR inhibitors in metastatic colorectal cancer (mCRC): Interaction among early tumor shrinkage, skin toxicities, and RAS status. 116
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 116
Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives. 113
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 112
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile 111
Neoplasie della testa collo nell’ anziano 109
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. 108
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 107
Rare histotypes of epithelial biliary tract tumors: A literature review 106
Safety of the combination Capecitabine plus Bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience. 105
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 104
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 103
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 102
Turbe della nutrizione: anoressia e cachessia. 100
Listening understanding and acting (lung): Focus on communicational issue in thoracic oncology 97
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 97
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 96
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 93
POLIMORPHISM OF METHYLENE-TETRAHYDROFOLATE REDUCTASE AND RISK OF LUNG AND COLON-RECTAL CANCER: A CASE CONTROL STUDY 90
Neoplasie della Testa e del Collo nell'anziano 89
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 88
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 85
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 85
Invecchiamento e cancro. 84
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study 84
“Lunga stazionarietà di malattia e clinical benefit con erlotinib in un paziente anziano, forte fumatore, affetto da carcinoma squamoso del polmone”. 83
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. 82
Use of nivolumab in elderly patients with advanced Non-Squamous NSCLC: results from the Italian Expanded Access Program (EAP) 81
Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings 80
Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice 75
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 75
Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database 74
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 73
FGFR a promising druggable target in cancer: Molecular biology and new drugs 72
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance. 71
Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review 68
Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study 68
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System 65
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System 64
Totale 13.126
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.072
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.072
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021215 0 0 0 0 0 0 0 0 0 95 71 49
2021/2022668 6 71 23 19 28 7 29 27 5 163 90 200
2022/20231.841 128 179 74 157 136 184 49 129 724 9 49 23
2023/2024495 25 80 32 29 23 175 60 4 2 21 8 36
2024/20252.055 34 22 34 112 104 82 57 451 473 156 192 338
2025/20266.420 332 378 474 431 551 1.403 862 914 824 251 0 0
Totale 13.541